| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802960401037 | 296040103 | EVECET PR.TAB 2MG/TAB BTx28 σε Blisters (PVC/PCTFE-Al) σε Blisters (PVC/PCTFE-Al) | 3.58 | 3.76 | 5.18 |
| 05/2018 | 2802960402034 | 296040203 | EVECET PR.TAB 3MG/TAB BTx28 σε Blisters (PVC/PCTFE-Al) σε Blisters (PVC/PCTFE-Al) | 5.12 | 5.37 | 7.40 |
| 05/2018 | 2802960403031 | 296040303 | EVECET PR.TAB 4MG/TAB BTx28 σε Blisters (PVC/PCTFE-Al) σε Blisters (PVC/PCTFE-Al) | 6.83 | 7.16 | 9.87 |
| 05/2018 | 2802960404038 | 296040403 | EVECET PR.TAB 8MG/TAB BTx28 σε Blisters (PVC/PCTFE-Al) σε Blisters (PVC/PCTFE-Al) | 13.05 | 13.69 | 18.87 |
For the treatment of the signs and symptoms of idiopathic Parkinson's disease. Also used for the treatment of restless legs syndrome.
Ropinirole binds the dopamine receptors D<sub>3</sub> and D<sub>2</sub>. Although the precise mechanism of action of ropinirole as a treatment for Parkinson's disease is unknown, it is believed to be related to its ability to stimulate these receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that ropinirole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum.
Symptoms of overdose include agitation, chest pain, confusion, drowsiness, facial muscle movements, grogginess, increased jerkiness of movement, symptoms of low blood pressure (dizziness, light-headedness)upon standing, nausea, and vomiting.
Absolute bioavailability is 55%, indicating a first pass effect. Food does not affect the extent of absorption.
6 hours
Ropinirole is extensively metabolized by the liver to inactive metabolites, and less than 10% of the administered dose is excreted as unchanged drug in urine.
* 7.5 L/kg * 525 L
* 47 L/hr [after oral administration to Parkinson's disease patients and patients with Restless Legs Syndrome]